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Telomeres, stretches of repetitive DNA sequences associated with
specific DNA binding proteins at the ends of eukaryotic chromo-
somes, progressively shorten with every cell division because
DNA polymerase can not replicate the end of a linear template (the
‘End-replication Problem’) (Allsopp et al, 1995; Kipling, 1995).
Gradual telomere erosion has been suggested to be a ‘mitotic
clock’ and tumour suppressor mechanism, triggering senescence
and cell death when telomere reduction eventually destabilizes
chromosomes (Harley, 1991). Acquisition of the immortal pheno-
type is an obligatory event for most human cancers and stabiliza-
tion of telomere length is thought to be a critical molecular
condition in the multistep pathway to cellular transformation and
immortalization (Newbold et al, 1982; Rhyu, 1995). Telomerase is
a ribonucleoprotein complex that, by the action of an internalized
RNA template (hTERC), a catalytic subunit (hTERT) and a
possible helper protein (hTEP1), adds telomeric DNA to the ends
of chromosomes, thereby halting their erosion with each cell divi-
sion (Feng et al, 1995; Harrington et al, 1997; Nakamura et al,
1997). Based on the results of the conventional telomerase poly-
merase assay and of the sensitive telomeric repeat amplification
protocol (TRAP assay), which showed enzyme activity in over
85% of human cancer tissues and immortal cell lines but not in
normal primary cell cultures or normal tissues, it was extrapolated
that, putatively by a genetic event, telomerase activity is ‘turned
on’ during in vivo tumorigenesis (the ‘classic’ telomerase reac-
tivation model), thereby freeing premalignant cells from the
restraint of their finite life span (Counter et al, 1992; Kim et al,
1994). However, extensive TRAP analyses and RNA expression
studies of hTERT – the only rate-limiting subunit discovered today
– revealed that many normal cell types too, of which the majority
of cancers are derived from, are weakly telomerase-positive in
vivo (Counter et al, 1995; Harle-Bachor and Boukamp, 1996;
Kolquist et al, 1998; Ramakrishnan et al, 1998). Other cell types,
scored telomerase-negative in vivo, appear competent to express
telomerase when subjected to a sufficient proliferative stimulus in
vitro (Belair et al, 1997; Greider, 1998). Therefore, it is currently
only valid to apply the classic reactivation model to a particular
organ system when the cell of origin is effectively telomerase-
negative, not just in its in vivo state but also when subjected to
‘excessive’ growth stimulation (‘revised’ classic model or type 1
scenario) (Wynford-Thomas, 1999).
Cutaneous malignant melanoma (CMM) is a cancer originating
in melanocytes, a skin-cell type derived from the neural crest
(Quevedo and Fleischmann, 1980). CMM is characterized by a
rapid growth rate, the invasion of local tissue and a propensity for
metastasis. The incidence and mortality rates of CMM are rising
dramatically throughout the world (Boyle et al, 1995). Cytogenetic
and molecular studies in CMM suggest that mutations in several
genes are critical in the susceptibility, development and progres-
sion of CMM, which is believed to develop in a multistep fashion
(Albino, 1995). CMM evolves from melanocytic precursors via
the formation of clinicopathologically defined intermediate lesions
of varying stability (Briggs, 1985). Interestingly, an increase in
telomerase activity has been found during progression of
melanocytic lesions from melanocytic naevi to metastatic CMM,
indicating that telomerase activity may play a role in tumour initi-
ation and progression (Taylor et al, 1996; Bosserhoff et al, 1997;
Glaessl et al, 1999; Parris et al, 1999) (see Table 1). However, it is
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merely quantitatively up-regulated during CMM carcinogenesis,
because it is not known whether epidermal melanocytes are
competent to express telomerase in physiological circumstances.
To investigate the competence of epidermal melanocytes to
express telomerase, we determined telomerase activity and expres-
sion of hTERT, hTEP1 mRNA and hTERC RNA, using the TRAP
assay and reverse transcription polymerase chain reaction (RT-
PCR) respectively, in proliferating melanocyte cultures.
MATERIALS AND METHODS
Melanocyte cultures
Ten primary MCCs were obtained from neonatal foreskins and
cultured in M199 medium supplemented with 2% fetal calf serum
(FCS), 10–9 M choleratoxin, 10 ng ml–1 basic fibroblast growth
factor, 10 mg ml–1 insulin, 1.4 mM hydrocortisone and 10 mg ml–1
transferrin, as described previously (Naeyaert et al, 1991). Post-
primary MCCs were maintained in low calcium (0.03 mM) M199
medium supplemented with the aforementioned additives and 10%
FCS. Assessment of growth was performed in triplicate by cell
counting using a Bürker haemocytometer and a Coulter counter,
according to standard procedures. The melanocytic nature of the
MCC cells was evidenced by indirect immunofluorescence using
the NKIbeteb antibody (Monosan, The Netherlands) against the
(pre)melanosomal silver protein, as described (Lambert et al,
1998). For analysis of telomerase activity and transcript expres-
sion, cell extracts and total RNA were collected from proliferating
MCCs during logarithmic phase of growth. A precise assessment
of the proliferating cell fraction in matched cytospins of these
MCCs was facilitated by a streptavidin–biotin–peroxidase-based
immunocytochemical approach with the monoclonal antibodies
Ki-S5 and Ki-S2 (provided by Prof. Dr R Parwaresch, Institute of
Haematopathology, University of Kiel, Germany). Ki-S5 binds to
a formalin-resistant epitope of the Ki-67 antigen, yields identical
results in fresh material and fixed tissues, and, unlike Ki-67, does
not cross-react with cytoplasmic antigens of epithelial cells
(Kreipe et al, 1993). Ki-S2 binds to an epitope that is present
during the entire cell cycle, with exception of the rate-limiting G1
phase, thereby being a more accurate marker of the actively prolif-
erating cell fraction than Ki-S5 (Rudolph et al, 1998). Human
dermal foreskin fibroblasts, as well as G 361 melanoma cells and
HL-60 cells served as telomerase-negative and -positive cells
respectively.
Non-isotopic TRAP assay
Lysate preparation and the TRAP assay were performed as
described previously (Dhaene et al, 1998), with minor modifica-
tions. Briefly, 106 MCC cells were lysed by retro-pipetting in
200 ml of ice-cold lysis buffer. After 30 min of incubation on ice,
the lysates were centrifuged at 14 000 g for 60 min at 4°C, and the
total protein concentration of the supernatant standardized
according to Bradford (approximately 1 mg ml–1). Six microlitres
of supernatant were used for the TRAP assays. After an initial
incubation period (30°C for 30 min), telomerase products were
amplified using TS and ACX primers (35 cycles at 94°C for 30 s,
53°C for 30 s and 72°C for 30 s). Assay specificity was confirmed
by inclusion of an RNAase preincubation control step, and Taq
inhibition checked by including the 36 bp internal control.
Presence of telomerase inhibitors was tested by mixing negative
MCC extracts with positive HL-60 extracts in a 1:1 ratio. Every
assay included a telomerase-positive sample (HL-60), a telom-
erase-negative sample (dermal fibroblasts) and an extract-free
sample to detect PCR amplification of primer dimers. Amplicons
were electrophoresed on a 12.5% non-denaturing polyacrylamide
gel (19:1), stained with ethidium bromide and analysed by the
CCD camera-coupled Gel Doc 1000 Molecular Analyst Software
package (Bio-Rad Laboratories GmbH, Germany).
RT-PCR analysis of telomerase transcripts
Total RNA was isolated using Tri Reagent (Sigma Chemical Co.,
USA). cDNAs were synthesized from 1 mg of total RNA in RT
buffer containing random hexamers (Pharmacia Biotech, Sweden)
and the MMLV reverse transcriptase (Promega Benelux BV, The
Netherlands). For amplification of hTEP1, hTERC and hTERT
transcripts, primers and cycling conditions were applied, as
described previously (Dhaene et al, 1999) (see also Table 2).
Briefly, primer pairs TLP1/U4792 and TLP1/L5102 (333 bp
amplicon) and HTR-F and HTR-R (112 bp amplicon) were used to
detect hTEP1 and hTERC cDNA. hTERT cDNA was looked for
using two sets of primers. Primers LT5 and LT6 (145 bp amplicon)
amplify a telomerase-specific hTERT sequence (T-motif), whereas
primers TERT-2164S and TERT-2620A (457 bp amplicon)
amplify two conserved reverse transcriptase motifs (A and B),
thereby spanning two splice sites, which cause 36 bp and 182 bp
transcript deletions (a and b splice sites respectively). During first
and second hTERT cDNA amplification b-actin-specific internal
control primers (95 bp) were added at 72°C of cycle 13 and 15
respectively. Amplification of genomic DNA was controlled by
omitting the RT-step in appropriate control reactions.
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Table 1 Overview of telomerase activity (%) in melanocytic lesions, as reported in the literature
Taylor et al, Bosserhoff et al, Ueda et al, Parris et al, Glaessl et al,
1996 1997 1997 1999 1999
Melanocytic naevi – 5/17 (29.4%) – – 10/36 (27.7%)
Atypical naevi – – – – 4/5 (80%)
Spitz’s naevi – – – – 2/3 (66%)
Primary CMM 5/6 (83.3%) 7/11 (64.0%) 4/5 (80.0%) 22/32 (69%) 28/31 (90.3%)
CMM metastasis 1/1 (100%) 8/10 (80.0%) – – 12/13 (92.3%)
CMM cell lines – 8/8 (100%)a – – 8/8 (100%)a
aMel Im, HTZ-19, Mel Ei, Mel Wei, Mel Juso, Mel Ju, Mel Ho, SK Mel 28.RESULTS
Immunofluorescence with the melanosome-specific NKIbeteb
antibody confirmed the melanocytic nature of cultured MCCs,
with signals confined to the perinuclear area, along the dendrites
and in the tips of the dendrites. The proliferative rate was found to
be approximately 4.5–5 days per population doubling (data not
shown). In MCCs in logarithmic phase of growth 60% and 30% of
cells showed Ki-S5 and Ki-S2 nuclear staining respectively
(Figure 1A,B).
A non-isotopic TRAP procedure was used to assay telomerase
activity in extracts of proliferating MCCs. In a previous report, the
sensitivity of our ethidium bromide-based procedure was evalu-
ated, and 100 telomerase-positive cells were found to be sufficient
for the detection of telomerase activity (Dhaene et al, 1998). In the
present study, results reproducibly showed no telomerase activity
in extracts of proliferating MCCs and of dermal fibroblasts (Figure
2A). False-negative results due to the presence of Taq DNA poly-
merase inhibitors or telomerase inhibitors were excluded since the
internal control could be amplified and ladder signals of telom-
erase-positive HL-60-extracts did not disappear after mixing with
telomerase-negative extracts of MCCs (Figure 2B). In extracts of
G 361 melanoma cells, like with HL-60 cells, strong enzyme
activity was detected.
RT-PCR, specifically amplifying transcripts of the internal RNA
template hTERC, of the catalytic subunit hTERT and of an associ-
ated protein hTEP1, was used to study expression of the various
components of the telomerase complex in proliferating MCCs.
Under all applied cycling conditions, PCR products were not
generated when omitting the RT step, making DNAase treatments
unnecessary (data not shown). We detected expression of hTERC
and hTEP1 in G 361 cells and in proliferating MCCs. In contrast,
we observed the 145 bp hTERT RT-PCR product only in the
cancer-derived cell lines but not in fibroblasts nor in any of the
MCCs (Figure 3A). We further applied the primers designed by
Ulaner et al (1998) that span both the b and the a splice site,
causing 182 bp and 36 bp deletions respectively. PCR with the
2164/2620 primers revealed alternative splicing of the hTERT
gene in all neoplastic cells (Figure 3B). Among the four amplifica-
tion products, representing the full-length hTERT transcript
(457 bp), the a-deleted transcript (421 bp), the b-deleted transcript
(275 bp), and the a- and b-deleted transcript (239 bp), the
b-deleted transcript was clearly over-represented, while the
a-deleted transcript was hardly detectable. Only the full-length
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Table 2 Oligonucleotides and cycling conditions used for detection of hTEP1, hTERC and hTERT
transcripts by RT-PCR
Oligonucleotides C°/time (sec) Cycles
hTEP1 cDNA amplification (333 bp)a 94°/30 30
TLP1/U4792: 5¢-CTTGGAATTGGGTCTGGTCTCTCG-3¢ 62°/45
TLP1/L5102: 5¢-CACAGCAGTAGGGGATGAGGAAAC-3¢
hTERC cDNA amplification (112 bp)a 94°/30 25
HTR-F: 5¢-CCTAACTGAGAAGGGCGTAGGC-3¢ 65°/60
HTR-R: 5¢-CTAGAATGAACGGTGGAAGGCG-3¢
First round hTERT cDNA amplification (145 bp)b 94°/20
LT5: 5¢-CGGAAGAGTGTCTGGAGCAA-3¢ 68°/40 33
LT6: 5¢-GGATGAAGCGGAGTCTGGA-3¢ 72°/30
Second round hTERT cDNA amplification (457 bp)b 95°/25
TERT-2164S: 5¢-GCCTGAGCTGTACTTTGTCAA-3¢ 68°/50 35
TERT-2620A: 5¢-CGCAAACAGCTTGTTCTCCATGTC-3¢ 72°/50
b-actin cDNA amplification (95 bp)b (see Materials and Methods)
774: 5¢-GGGAATTCAAAACTGGAACGGTGAAGG-3¢
775: 5¢-GGAAGCTTATCAAAGTCCTCGGCCACA-3¢
aNakayama et al (1998); bUlaner et al (1998).
A B
Figure 1 Immunocytochemistry of cytospinned cultured human melanocytes (streptavidin–biotin–peroxidase technique, original magnification ´100), showing
Ki-S5 staining (A) in 60% of nuclei, and Ki-S2 immunoreactivity (B) in 30% of melanocytes (arrows)transcript is thought to code for active reverse transcription
activity. As expected, no 457 bp amplicon but also none of the
other spliced variants were detected in any of the MCCs and
fibroblasts. Overall, the absence of hTERT expression in prolifer-
ating MCCs was confirmed using two different RT-PCR protocols.
DISCUSSION
Regarding their telomerase state, normal progenitor cells of telom-
erase-positive tumours can be subdivided into three categories
(Wynford-Thomas, 1999). The cell of origin constitutively
expresses a low (Type 3), a high (Type 2) or no (Type 1) level of
telomerase activity. The latter state is only acceptable when the
cell type is shown to be effectively telomerase-negative when
subjected to ‘excessive’ growth stimulation. De novo expression
(Type 1 scenario) vs quantitative up-regulation (Type 2 and 3
scenarios) of telomerase activity, occurring during carcinogenesis,
are supposed to be fundamentally distinct biological processes as
to what the tightness of telomerase regulation is. This study
addressed the question whether epidermal melanocytes are compe-
tent to express telomerase under proliferation-inducing conditions.
Methodologically, we had to deal with an ongoing debate.
Indeed, conflicting reports have appeared concerning cell cycle-
dependent regulation of telomerase activity in cancer cells and
telomerase-expressing normal cells, like T lymphocytes. Most
groups found that telomerase is largely absent in cells that truly
exit the cell cycle (Go), and that telomerase activity does not vary
significantly at the other cycle stages (Mantell and Greider, 1994;
Holt et al, 1996, 1997). In contrast, others concluded that Go-cells
have detectable telomerase, whilst maximal telomerase activity is
present in S phase cells (Yamada et al, 1996; Zhu et al, 1996). To
circumvent this discrepancy, and to obtain an estimation of the
least possible percentage of telomerase-positive melanocytes,
cytospins were stained with the monoclonal antibody Ki-S2,
which excludes Go-cells and cells in the rate-limiting G1 phase
(Rudolph et al, 1998). Thirty per cent of melanocytes showed Ki-
S2 immunoreactivity, which means that, the length of the S phase
equalling the lengths of both the G2 and the M phase, at least
1.53105 melanocytes per 200 ml CHAPS lysis buffer (4500 cells
in assay) could have had detectable telomerase activity. We previ-
ously determined that telomerase activity of a minimum of 104
telomerase-positive cells 200 ml–1 CHAPS lysis buffer (100 cells in
assay) was detected in the ethidium bromide-based TRAP assay
(Dhaene et al, 1998), indicating that the observed lack of telom-
erase activity in proliferating MCCs reported here, was substan-
tial, and did not result from insufficient sensitivity of the assay.
Moreover, using two different RT-PCR protocols, neither full-
length nor spliced hTERT transcripts were detected in any of the
ten MCCs, thereby further corroborating our conclusions. Indeed,
hTERT encodes the proteinaceous subunit of the telomerase
complex, which, by a reverse transcriptase-like activity, catalyses
the synthesis of telomeric repeats. Whereas hTERT expression can
be found in the absence of telomerase activity, suggesting the
occurrence of post-translational modification, telomerase activity
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Figure 2 Representative non-isotopic TRAP assay results of telomerase activity status in supernatant from melanocyte cultures (MCC) and G 361 melanoma
cells (inverted digitized images). (A) Extracts of HL-60 cells and foreskin fibroblasts (FB) served as positive and negative control respectively. For every assay, a
36 bp internal control band is visible (arrow). A RNAase-treated control (+ at top), showing loss of signal, doubled each positive sample. Lysis buffer alone (Lb)
was applied as another negative control. The assay result is indicated at the bottom of the figure. (B) Failure of the telomerase negative extracts of MCCs to
inhibit the telomerase-positive HL-60 extracts in a mixing experiment. Telomerase-negative extracts of MCC 221, 222 and 225 mixed with HL-60 extract in a 1:1
ratiois always accompanied by hTERT expression (Nakamura et al,
1997). In G 361 cells, as is known for HL-60 cells, three additional
transcript variants were found. However, the significance of the
distribution pattern of the spliced products awaits knowledge on
the role of the individual mRNA variants and elucidation whether
these variants are translated into biologically functional proteins.
Thus, our report adds epidermal melanocytes to the list of cell
types, including fibroblasts, mammary epithelium and embryonic
kidney cells, which do not express telomerase activity even when
proliferating actively (Counter et al, 1992; Kim et al, 1994).
Telomerase activity has been detected in the majority of primary
CMMs (range 64.0–90.3%) and CMM metastases (range
80–100%), indicating that telomerase may play a role in
melanoma carcinogenesis (see Table 1). Accounting for over 50%
of the cases, CMM is generally believed to derive de novo in
normal skin from fully dendritic mature epidermal melanocytes
(Ackerman, 1988). Thus, our data suggest that melanocytes are
physiologically telomerase-incompetent, and that telomerase is
pathologically reactivated during melanoma carcinogenesis. This
pathogenic pathway corresponds with the aforementioned revised
classic model (Type 1 scenario), in which the cell of origin is
telomerase-negative, and in which telomerase reactivation is
directly selected in precrisis tumour cell populations, resulting in
an immortal tumour with telomeres stabilized at or above the crisis
threshold (Wynford-Thomas, 1999). On the other hand, the spatial
association of a subset of CMMs with benign naevi points to a
possible malignant transformation of naevus cells (Hastrup et al,
1991). Whilst telomerase activity has been found to increase from
benign melanocytic naevi to atypical naevi and further to CMM
and metastatic CMM cells (see Table 1), both the reactivation and
the up-regulation pathway are difficult to defend, since the
telomerase-status of naevus cells is uncertain. It is worthwhile
mentioning that it has been hypothesized that stem cells – either a
pluripotential perineural cell within the neurocutaneous unit, or a
committed melanoblast – are precursors of melanocytes, in both
normal and abnormal differentiation, and that stem cells could be
regarded as possible precursors of tumour cells (Cramer, 1991;
Greaves, 1996). Stem cells are considered telomerase-competent,
meaning that, if CMM would develop from it, there is no need for
reactivation of telomerase. A latter scenario is currently envisaged
as a Type 2 conceptual framework (Wynford-Thomas, 1999).
Mechanisms regulating telomerase reactivation are poorly
understood. It is classically stated that telomerase up-regulation is
forced by critical telomere erosion beyond the point where cell
multiplication normally stops. An in vitro situation is seen during
continuous culture of SV-40 Large T antigen or HPVE6/E7-
transformed telomerase-negative human cells which eventually
undergo ‘crisis’ – the condition in which cellular chromosomes are
characterized by ultra-short telomeres and that coincides with
telomerase activation (Wright et al, 1989; Counter et al, 1992). At
present it is not known whether HPV viruses, for which DNA
sequences have been found in some CMMs, can be responsible for
an in vivo equivalent of crisis during CMM carcinogenesis
(Scheurlen et al, 1986; Klingel et al, 1987; Takamiyagi et al,
1998).
The great majority of individual studies showed a significant
positive association between incidence of CMM and high levels of
intermittent solar exposure, suggesting that even a single event
may suffice to stimulate tumour growth (Elwood and Jopson,
1997). All the evidence suggests that it is the UV portion of the
solar spectrum which is relevant. However, the contribution of
specific wavelength bands (290–320 nm for UVB and 320–
400 nm for UVA radiation) and the action spectrum for melanoma
induction in humans remains unknown (International Agency for
Research on Cancer, 1992). It has been reported that telomerase
is activated during radiation-induced malignant transformation
of human cells and in mouse skin (Pandita et al, 1996;
Balasubramanian et al, 1999), and in the sun-exposed skin in
humans, indicating a possible modulation of telomerase activity by
UV exposure (Taylor et al, 1996; Ueda et al, 1997). The prediction
Absence of telomerase in cultured melanocytes 1055
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Figure 3 (A) Representative results of RT-PCR analysis for the expression
of hTERC, hTEP1 and hTERT in HL-60 cells (positive control), G 361
melanoma cells and cultured melanocytes (MCC). Expression of hTERT
mRNA was determined using primers LT5/LT6 (145 bp amplicon). Amplicons
were electrophoresed on a 2% agarose gel. (B) Representative results of RT-
PCR analysis for the expression of hTERT using primers TERT-2164 and
TERT-2620. Amplicons were electrophoresed on a 6% polyacrylamide gel
(inverted digitized image). TRAP assay results for telomerase activity
(bottom), the 95 bp b-actin internal control amplicon (arrowheads), and length
markers (M) are indicatedis that one or more tumour suppressor genes prevent activation of
telomerase in normal human cells (deLange, 1998). Therefore, it
needs further study to find out if UV can directly eliminate such
genes, for which candidates are thought to locate on the short arm
of chromosome 3 (Cuthbert et al, 1999). Alternatively, telomerase
reactivation might be an epiphenomenon of UV light-induced
genotoxic stress, as proposed by adherents of the ‘co-selection
hypothesis’ (Kipling, 1997). In this report, we excluded that prolif-
erative behaviour, which both in vitro and in vivo is another effect
of UV light (Libow et al, 1988; Gilchrest et al, 1998), can co-select
telomerase activity. Finally, recent cloning and sequence analysis
of the hTERT gene promoter revealed the presence of binding sites
for transcription factors including the c-Myc proto-oncoprotein
(Cong et al, 1999). The latter activates telomerase by inducing
expression of its catalytic subunit, indicating that hTERT is a
target of c-Myc activity (Wu et al, 1999). Interestingly, altered
expression of c-myc has been reported in both cultured melanoma
cells and in tumour samples (Weterman et al, 1994).
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